From linked in
https://www.linkedin.com/feed/update/urn:li:activity:7449321437858983936/
TL;DR: this is not a valuation memo in any normal business sense. It is a philosophical cautionary essay about AI in diagnostics. Their basic point is: AI can become very good at the “game” of internal pattern recognition while still missing the real-world patient, context, accountability, and consequences.
In plain English, they are saying: don’t confuse a beautiful, high-performing AI system with actual clinical wisdom. They use Hesse to symbolize an elegant closed intellectual world detached from life, Gödel to argue that a complex system cannot fully validate itself from inside its own rules, and Wagner to warn that seamless integration can hide what is missing. Then they apply that to pathology: the slide is not the tumor, and the tumor is not the patient. So even a very impressive AI can be blind to the larger clinical reality.
Their practical message is pretty simple underneath the opera-and-philosophy packaging: medical AI needs external governance, real-world validation, visible responsibility, and explicit operating limits. They worry about feedback loops where AI-trained-on-AI drifts away from biology, about opaque tech companies/labs, and about diffused accountability when no one can say who actually owned a bad decision.
So, what are these guys thinking? Basically:
They are thinking “AI in pathology is powerful, but don’t let the elegance of the system hypnotize you.” This is much more a warning essay / governance manifesto than a practical commercial, reimbursement, or valuation analysis.
My blunt gloss: they’re saying the digital pathology / AI crowd risks building a very smart Castalia—brilliant at abstractions, weaker at remembering the patient in the bed.
See also PHILLIPS 2026
https://www.discoveriesinhealthpolicy.com/2026/04/phillips-et-al-in-science-diagnostics.html
See also CLAEYS PRINZI TIMBROOK 2026
https://www.discoveriesinhealthpolicy.com/2026/03/horizons-in-diagnostics-value-case.html
